SOHO 2021 | Second-generation BTK inhibitors and their clinical impact
Deborah M. Stephens
• 31 Aug 2021
Deborah M. Stephens, DO, of The University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, discusses second-generation Bruton’s tyrosine kinase inhibitors (BTKis) and outlines the impact that they have had in clinical settings. Dr Stephens compares the toxicity and safety profile of ibrutinib, a first-generation BTKi, with second-generation BTKis such as acalabrutinib and zanubrutinib, suggesting that second-generation BTKis may become a more favourable treatment option. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
